

SOFIE
From start to clinic

Current State of FAP Ligands for Diagnostic Use in Oncology

SOFIE Educational Webinar Series

6/14/23

Sherly Mosessian Ph.D.

Chief Scientific Officer

Sherly.Mosessian@sofie.com



Learning Objectives

1. Explain the significance of FAP as a target in oncology
2. Highlight the progress made to date with FAP targeting ligands for diagnostic use in oncology
3. Describe the current clinical trials and regulatory landscape for FAP targeting ligands



FAP as a target in oncology

FAP (Fibroblast Activation Protein)


Activated Fibroblasts express high levels of FAP

Fibroblasts become activated during wound repair and regeneration. Malignant tumors are recognized as “wounds that do not heal”



Among all the stromal cells, **cancer-associated fibroblasts (CAFs)** are dominant populations in the tumor microenvironment

FAP is highly expressed on the surface of CAFs

FAP is a great target due to its overexpression in most of the cancer types (90%)



Mori Y, Dendl K, Cardinale J, Kratochwil C, Giesel FL, Haberkorn U. FAPI PET: Fibroblast Activation Protein Inhibitor Use in Oncologic and Nononcologic Disease. Radiology. 2023 Jan 3;220749. doi: 10.1148/radiol.220749. Epub ahead of print. PMID: 36594838.




FAP protein expression in various cancer tissues

- FAP is highly expressed in an array of different cancers (stroma cells not typically tumor)
- FAP expression is detected in the tumor cells of sarcomas
- Noteworthy: Colorectal, GI/stomach, Thyroid/Oropharynx, Pancreas, Ovarian, Lung and Bladder/Urothelial show high expression of FAP in data displayed here

Note: FAP expression levels can vary based on sample size, sample location, sub-type of disease and stage of disease.

FAP targeting approaches

Antibody



Sibrotuzumab

Boehringer Ingelheim product for targeting various cancers

Results did not show sufficient efficacy in 2003 Phase II study

Roche and Molecular Partners AG have active studies in clinical trials involving antibodies

DPP-4 small molecule inhibitors




Talabostatin & Linagliptin

Talabostatin has shown some efficacy in Phase 2 but safety concerns paused further studies

Linagliptin is approved drug for type 2 diabetes

CAR T Cell Therapy




Car T Cell Therapy

FAP-targeting CAR-T cells genetically engineered to target CAFs in various solid cancers

Clinical trials are in early stages.

Pro-drug



AVA6000 – FAP α -Activated Doxorubicin

Phase 1 study active

Note: these are select examples, not a comprehensive list




Radiopharmaceuticals targeting FAP

Theranostics

Diagnostic: PET imaging to visualize cells expressing the target of interest (FAP). Short-lived radionuclide ^{68}Ga or ^{18}F

Therapeutic: Molecular targeted radio-ablation of cancer or cancer associated cells
Long-lived radionuclide ^{177}Lu , ^{225}Ac , ^{212}Pb or other beta or alpha particle emitters



The magic bullet. Theranostics target unique properties of cancer cells using different radionuclides for diagnosis and treatment.
Credit: Marina Spence/Nature Medicine


Carrie Arnold Nature News 2022



(Fibroblast Activation Protein Inhibitor)-**FAPI** family of compounds

SNMMI Image of the Year 2019


"A single radiotracer can identify nearly 30 types of cancer, allowing for new applications in noninvasive diagnosis, staging and treatment, according to research presented at the 2019 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). This honor goes to a team of researchers at University Hospital Heidelberg, Germany, showcasing the efficacy of the FAPI radiotracer."



JNM Best Clinical Article in 2021

Impact of ^{68}Ga -FAPI PET/CT Imaging on the Therapeutic Management of Primary and Recurrent PDAC


^{68}Ga -FAPI PET/CT results led to changes in TNM staging in 10 of 19 patients



Röhrich M, Naumann P, Giesel FL, Choyke PL, Staudinger F, Wefers A, Liew DP, Kratochwil C, Rathke H, Liermann J, Herfarth K, Jäger D, Debus J, Haberkorn U, Lang M, Koerber SA. Impact of ^{68}Ga -FAPI PET/CT Imaging on the Therapeutic Management of Primary and Recurrent Pancreatic Ductal Adenocarcinomas. J Nucl Med. 2021 Jun 1;62(6):779-786

SNMMI Image of the Year 2022

Representative case with acute anterior wall myocardial infarction: ^{68}Ga -FAPI-46



Johanna Diekmann, James Thackeray, Thorsten Derlin, Christoph Czerner, Tobias Ross, and Frank Bengel, Department of Nuclear Medicine, Hannover Medical School, Hannover, Niedersachsen, Germany; and Tobias Koenig, Jonas Neuser, Andreas Schaefer, Jochen Tillmans, and Johann Bauersachs, Department of Cardiology and Angiology, Hannover School of Medicine, Hannover, Niedersachsen, Germany.

FAP Radioligand as biomarker for FAP expression

What is a biomarker?

Live visualization and quantitation of FAP expression in humans


Why is this of value?

- Early diagnosis
- Disease staging
- Management of care
- Companion diagnostic
 - Enrich percent responders in therapy trials and in patient care
 - Patient selection assay for effective therapy
- Treatment monitoring




FAP IHC and PET signal validation- 2 independent studies for [68Ga]FAPi-46

Correlation between FAP immunohistochemistry score and ⁶⁸Ga-FAPi-46 PET SUVs across cancer and non-cancer tissues



Fibroblast activation protein positron emission tomography and histopathology in a single-center database of 324 patients and 21 tumor entities






Progress made to date with FAP
targeting ligands for diagnostic
use in oncology

Mounting interest and growth in published evidence with FAPI

Publication counts with keywords "FAPI" and "PET"



Publication analysis



of patients reported

Total Publications/Patients with
ALL FAP targeted
radiopharmaceuticals

5903

Publications/Patients with
FAPI family of compounds

5321

90%

4234- Oncology
1087- non-oncology



of publications


464

396

85%

Takeaway: FAPI family of compounds comprise the majority of publications and patient reported data to date (May 2023). *(Review articles are excluded)*



of patients/publications in various oncologic disease



GI cancers encompass majority of the patient numbers reported with FAPI

Meta Data Analysis of FAP radioligands in imaging

Takeaway: strong prelim data of performance in various cancers, especially GI/biliary/liver

 **diagnostics** 

Systematic Review

FAP PET versus FDG PET, CT or MRI for Staging Pancreatic-, Gastric- and Cholangiocarcinoma: Systematic Review and Head-to-Head Comparisons of Diagnostic Performances

Sophie E. M. Veldhuijzen van Zanten ^{1,*}, Kay J. Pieterman ^{1,†}, Bas P. L. Wijnhoven ², Ilanah J. Pruis ¹, Bas Groot Koerkamp ², Lydi M. J. W. van Driel ³, Frederik A. Verburg ¹ and Maarten G. J. Thomeer ¹



¹ Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands

² Department of Surgery, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands

³ Department of Gastroenterology and Hepatology, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands

* Correspondence: s.veldhuijzenanzanten@erasmusmc.nl

† These authors contributed equally to this work.

 **International Journal of Molecular Sciences** 

Review

Head-to-Head Comparison of Fibroblast Activation Protein Inhibitors (FAPI) Radiotracers versus [¹⁸F]F-FDG in Oncology: A Systematic Review

Giorgio Treglia ^{1,2,3,4,5,*}, Barbara Muoio ^{6,†}, Hessamoddin Roustaei ⁷, Zahra Kiamanesh ⁷, Kamran Aryana ⁷ and Ramin Sadeghi ⁷

¹ Clinic of Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland

² Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, 1011 Lausanne, Switzerland

³ Academic Education, Research and Innovation Area, General Directorate, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland

⁴ Faculty of Biology and Medicine, University of Lausanne, 1011 Lausanne, Switzerland


⁵ Faculty of Biomedical Sciences, Università della Svizzera italiana, 6900 Lugano, Switzerland

⁶ Department of Medicine and Oncology, Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland; barbara.muioio@eoc.ch

⁷ Nuclear Medicine Research Center, Mashhad University of Medical Sciences, 9919991766 Mashhad, Iran; roustaei@81@mums.ac.ir (H.R.); kiamaneshz@gmail.com (Z.K.); aryanak@mums.ac.ir (K.A.); sadeghi@81@mums.ac.ir (R.S.)

* Correspondence: giorgio.treglia@eoc.ch; Tel.: +41-(0)-8118919


† C.T. and B.M. share the first authorship.



Wang et al.
European Journal of Medical Research (2023) 28:34
<https://doi.org/10.1186/s40001-023-00997-9>

European Journal of Medical Research

REVIEW **Open Access**



[⁶⁸Ga]Ga-FAPI-04 PET MRI/CT in the evaluation of gastric carcinomas compared with [¹⁸F]-FDG PET MRI/CT: a meta-analysis

Yawen Wang ^{1†}, Wenhao Luo ^{2†} and Ye Li ^{3*}

State-of-the-art of FAPI-PET Imaging: A Systematic Review and Meta-Analysis

Martina Sollini
HUNIMED: Humanitas University

Margarita Kirienko
Fondazione IRCCS Istituto Nazionale dei Tumori


Fabrizia Gelardi (✉ fabrizia.gelardi@humanitas.it)
HUNIMED: Humanitas University <https://orcid.org/0000-0001-7120-333X>

Francesco Fiz
IRCCS Humanitas Research Hospital

Noemi Gozzi
Istituto Clinico Humanitas: Humanitas Research Hospital

Arturo Chiti
HUNIMED: Humanitas University

Hindawi
Contrast Media & Molecular Imaging
Volume 2022, Article ID 3948873, 9 pages
<https://doi.org/10.1155/2022/3948873>

WILEY |  Hindawi

Review Article

Could Fibroblast Activation Protein (FAP)-Specific Radioligands Be Considered as Pan-Tumor Agents?

Hessamoddin Roustaei ¹, Zahra Kiamanesh ¹, Emran Askari ¹, Ramin Sadeghi ¹, Kamran Aryana ¹ and Giorgio Treglia ^{2,3,4}

¹Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

²Ente Ospedaliero Cantonale, Bellinzona, Switzerland

³Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland

⁴Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland

Correspondence should be addressed to Giorgio Treglia; giorgiomednuc@libero.it


> *Front Oncol.* 2023 Feb 17;13:1093861. doi: 10.3389/fonc.2023.1093861. eCollection 2023.

Comparison of ⁶⁸Ga-FAPI and ¹⁸F-FDG PET/CT for the diagnosis of primary and metastatic lesions in abdominal and pelvic malignancies: A systematic review and meta-analysis


Xue Liu ¹, Huiting Liu ¹, Caijiang Gao ¹, Wenbing Zeng ²

Affiliations + expand

PMID: 36874127 PMCID: [PMC9982086](https://pubmed.ncbi.nlm.nih.gov/PMC9982086/) DOI: [10.3389/fonc.2023.1093861](https://doi.org/10.3389/fonc.2023.1093861)



Comparison of FAPI vs. FDG in oncological PET-imaging




Pancreatic Cancer

Changes in care management/staging due to FAPI

TABLE 2
Comparison of ceCT-Based and ⁶⁸Ga-FAPI PET/CT-Based TNM Staging of 19 Patients with Primary and Recurrent/Progressive PDAC

Patient	Clinical indication	TNM stage (CT-based)	TNM stage (FAPI PET-based)	Additional finding in FAPI PET	Staging change
1	Relapse/progression	T1 N2 M1 (LYM, PUL)	T1 N0 M1 (LYM)	(Recurrent) mediastinal lymph node metastases	Up
2	Relapse/progression	T4 N0 M1 (PER)	T4 N0 M1 (PER)	None	None
3	Relapse/progression	T3 N0 M0	T3 N0 M1 (OSS)	Bone metastasis	Up
4	Relapse/progression	T4 N0 Mx	T4 N0 M1 (PER)	Peritoneal carcinosis	Up
5	Primary staging	T1 N0 M0	T1 N0 M0	None	None
6	Relapse/progression	T3 N0 M0	T3 N0 M0	None	None
7	Relapse/progression	T4 N0 Mx	T4 N0 M0	None	None
8	Primary staging	T4 N0 Mx	T4 N0 M0	None	None
9	Primary staging	T4 N0 M0	T4 N0 M0	None	None
10	Relapse/progression	T2 N0 M0	T0 N0 M0	No local recurrence (T0)	Down
11	Relapse/progression	T4 N0 M1 (LYM, HEP)	T4 N2 M1 (LYM, HEP, OSS)	Abdominal lymph node metastases, 2 more liver metastases, bone metastasis	Up
12	Primary staging	T4 N0 Mx	T4 N0 M0	None	None
13	Primary staging	T3 N0 M0	T3 N0 M0	None	None
14	Relapse/progression	T4 N2 M1 (HEP)	T4 N2 M1 (HEP, PER)	Peritoneal carcinosis	Up
15	Primary staging	T4 N2 Mx	T4 N2 M1 (PER, PLE)	Pleural carcinosis, peritoneal carcinosis, liver metastases	Up
16	Relapse/progression	T0 N2 M1 (LYM, HEP)	T0 N2 M1 (LYM, HEP, OSS)	Bone metastasis	Up
17	Relapse/progression	T2 N0 Mx	T2 N0 M1 (HEP, PUL)	Liver metastases without CT correlate, pulmonary metastasis	Up
18	Primary staging	T1 N0 Mx	T1 N0 M0	None	None
19	Relapse/progression	T4 Nx M1 (PER)	T4 N1 M1 (PER, OSS, HEP)	Lymph nodes definable from tumor conglomerate, bone metastases, liver metastases	Up


FDG and FAPI side by side comparison in same patients



Positron emission tomography and computed tomography with [68Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer. Yizhen Pang et al. 2021

Impact of 68Ga-FAPI PET/CT Imaging on the Therapeutic Management of Primary and Recurrent Pancreatic Ductal Adenocarcinomas Manuel Rohrich et al, 2021

Gastric Cancer



Kuten et al. 2022

Lesion location	¹⁸ F-FDG PET-CT		⁶⁸ Ga-FAPI PET-CT		p value
	Mean	Median (min–max)	Mean	Median (min–max)	
Primary cancer	8.4	7.5 (0.0–19.0)	14.6	13.2 (4.7–33.0)	<0.001
Peritoneal metastasis	3.1	2.6 (0.0–17.8)	10.7	8.1 (3.5–27.4)	<0.001
Lymph node metastasis	4.9	3.9 (0.0–17.6)	9.9	8.3 (0.0–21.5)	0.006
Lung metastasis	1.23	4.0 (0.0–3.7)	0.0	4.5 (2.5–5.0)	0.109
Liver metastasis	5.0	4.7 (0.0–14.8)	12.2	8.5 (0.0–55.0)	0.002
Bone metastasis	4.87	0.0 (0.0–14.5)	20.3	13.4 (3.4–62.0)	0.018

Wilcoxon signed ranks test was used

Comparison of 68Ga-FAPI PET/CT and 18F-FDG PET/CT Modalities in Gastrointestinal System Malignancies with Peritoneal Involvement. Elboga et al

FDG and FAPI side by side comparison in same patients





FIGURE 2. Comparison of visual assessment between ⁶⁸Ga-FAPI PET and ¹⁸F-FDG PET. n(n) in each bar refers to patient number (scores); M = metastases.


Comparison of 68Ga-FAPI and 18F-FDG Uptake in Gastric, Duodenal, and Colorectal Cancers. Pang et al.

Influence of Cirrhosis on ^{68}Ga -FAP PET/CT in Intrahepatic Tumors



- In a secondary analysis of a prospective trial, 48 patients without cirrhosis underwent ^{68}Ga -FAP PET/CT and 39 patients with cirrhosis underwent ^{68}Ga -FAP and ^{18}F -FDG PET/CT.
- Patients with cirrhosis had higher uptake of ^{68}Ga -FAP in the liver than patients without cirrhosis (average SUV, 1.4 [IQR, 0.6–2.9] vs 0.5 [IQR 0.4–2.7]).
- ^{68}Ga -FAP PET/CT identified 104 of 106 (98%) and 66 of 71 (93%) intrahepatic tumors in patients with and those without cirrhosis, which was higher than the 41% of tumors identified with ^{18}F -FDG PET/CT in patients with cirrhosis.

Initial Evaluation of [¹⁸F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions



Tadashi Watabe et al. J Nucl Med 2023;jnumed.123.265486

Challenges to overcome



PUBLICATIONS

- Many case studies. Shortage of larger cohort studies
- Many retrospective/compassionate use studies
- Use of various FAP targeting compounds (FAPI-04 for example is an older generation instead of FAPI-46 or FAPI-74)

ANALYSIS


- Comparison to FDG as the accepted standard instead of standard of care imaging
- Much emphasis on lesion number detection and less on management of care

Pitfalls and common findings in ⁶⁸Ga-FAPI-PET – A pictorial analysis

Lukas Kessler¹, Justin Ferdinandus¹, Nader Hirmas¹, Fadi Zarrad¹, Michael Nader¹, David Kersting¹, Manuel Weber¹, Sandra Kazek¹, Miriam Sraieb¹, Rainer Hamacher², Katharina Lueckerath¹, Lale Umutlu³, Wolfgang P Fendler¹, Christoph Rischpler¹

University Hospital Essen

Common pitfall findings were **degenerative lesions** mostly associated to joints and vertebral bones




Non-oncologic incidental uptake on FAPI PET/CT imaging

Masatoshi Hotta[✓], Angela C Rieger[✓], Mahbod G Jafarvand[✓], Nandakumar Menon[✓], Andrea Farolfi[✓], Matthias R Benz[✓], Jeremie Calais[✓]

Published Online: 13 Jul 2022 • Doi: <https://doi.org/10.1259/bjr.20220463>

UCLA

In this review article, they describe for each organ system the patterns of physiological FAPI uptake and the main causes of nononcological uptake reported from the literature



Considerations

- Identifying and pursuing indications that address an area of unmet need
- Focusing on FAP ligand's impact on management of care
- For each disease area identifying value in:
 1. Detection of primary lesion
 2. Detection of lymph node mets
 3. Detection of distant metastasis
 4. Treatment monitoring
- Confirming identity of lesions seen by FAP PET not simply # of lesions
- Pursuing value of FAP ligands for imaging as companion diagnostics for RLT and non-RLT in oncology and non oncology




Current State of Clinical Development & Regulatory for FAP targeting ligands

FAP targeting radioligands with clinical data

Affiliation	Product	Diagnostic	Therapy
SOFIE	FAPI family of compounds	[⁶⁸ Ga]FAPI-46 [¹⁸ F]FAPI-74	
Heidelberg University	FAPI family of compounds		FAPI-46 (alpha/beta)
Novartis	FAP-2286	[⁶⁸ Ga]FAP-2286	[¹⁷⁷ Lu]FAP-2286
Point Biopharma	PNT6555	[⁶⁸ Ga]PNT6555	[¹⁷⁷ Lu]PNT6555
Yantai LNC Biotech	EB-FAPI/LNC1004		[¹⁷⁷ Lu]LNC1004
Philogen	OncoFAP	[⁶⁸ Ga]OncoFAP	[¹⁷⁷ Lu]OncoFAP
3BP			3BP-3940
	SA.FAPI	[⁶⁸ Ga]DOTAGA(SA.FAPI) (variations)	[¹⁷⁷ Lu]DOTAGA(SA.FAPI) (variations)

Note: 3BP, Ratio Therapeutics and other industry groups have additional FAP assets not demonstrated here.
This list contains products under clinical studies



FIBROBLAST ACTIVATION PROTEIN IMAGING

CONSULTING EDITOR
ABASS ALAVI

EDITORS
RODNEY J. HICKS
FREDERIK L. GIESEL
KEN HERRMANN

July 2023




Review

> PET Clin. 2023 Jul;18(3):429-439. doi: 10.1016/j.cpet.2023.02.010. Epub 2023 Mar 27.

Current State of Clinical Trials and Regulatory Approvals with Fibroblast Activation Protein Targeting Interventions

Sherly Mosessian¹, Jessica D Jensen², Aaron S Enke³




ClinicalTrials.gov

ClinicalTrials.Gov is the Largest clinical trials database, holding registrations from over **329,000** trials from **209 countries**

- 1997 The Food and Drug Administration Modernization Act of 1997 mandates a clinical trials registry
- 2000 ClinicalTrials.gov comes online
- 2007 Food and Drug Administration Amendments Act of 2007 section 801 mandates registration and penalty for noncompliance
- 2009 Reporting results as mandatory






Search results with keywords “FAP” and “Fibroblast Activation Protein” resulted in 37 studies. Further classification of the results broke down the data into 21 diagnostic studies with PET, PET/CT, four studies in radioligand therapy, eight therapeutic studies in non-radioligand therapy, followed by four studies under Other. The Other studies include three completed genetic studies and one biologic intervention study currently active.

Industry sponsored trials with FAP radioligands for imaging & therapy


Sponsor	Study Title	Study type	Intervention(s)	Trial Phase
SOFIE	Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers	Diagnostic	[18F]FAPI-74	Phase 2
SOFIE	Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma	Diagnostic	[68Ga]FAPI-46	Phase 2
Novartis	A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE)	Theranostic	[68Ga]-FAP-2286 [177Lu]-FAP-2286	Phase 1/Phase 2
POINT Biopharma	FAPI Radioligand Open-Label, Phase 1 Study to Evaluate Safety, Tolerability and Dosimetry of [Lu-177]-PNT6555; A Dose Escalation Study for Treatment of Patients With Select Solid Tumors (FRONTIER)	Theranostic	[68Ga]-PNT6555 [177Lu]-PNT6555	Phase 1

Diagnostic studies by disease type




- Oncology encompasses the largest number of diagnostic studies

Diagnostic studies by Product and Trial Phase



- Majority of the studies are in Phase 0/1 Investigator Initiated Studies
- 2 diagnostic agents are the most advanced in Phase 2: [18F]FAPI-74 and [68Ga]FAPI-46

SOFIE's Product Pipeline



Family of compounds



Gallium-68 isotope

Compound #46

- Lead **Gallium-68** labeled compound
- 68 minutes half life
- 60 patients planned; **21 patients imaged**
- Phase 2 study in patients with Pancreatic Ductal Adenocarcinoma (PDAC), initiated May 2022
- Four clinical sites selected and activated
 - NYU Langone
 - Mayo Clinic
 - UCLA
 - BAMF Health


Family of compounds



Fluorine-18 isotope

Compound #74


- Lead **Fluorine-18** labeled compound
- 110 minutes half life
- 120 patients planned; **1 patient imaged**
- Phase 2 study in patients with hepatocellular carcinoma, gastric cancer, cholangiocarcinoma, colorectal cancer and pancreatic cancer, initiated May 2023
- MGH launched as the first site. Four additional sites in activation process
- Automated synthesis and consumables available with Trasis Mini-AIO and AIO



SOFIE's FAPI Global Outreach Program

- 39 Countries
- 227 research studies
- 126 unique institutions
- Compounds: [^{18}F]-FAPI-74 and [^{68}Ga]-FAPI-46

Studies by Country



FAPI studies by country. 39 countries are part of our FAPI Global Outreach Program, conducting studies with FAPI. The countries conducting the highest number of studies in descending order are: Germany (30), United States (27), Netherlands (16), France (14), Sweden (11) and Italy (10).



SOFIE's FAPI Global Outreach Program

Gain access to GMP grade precursor and reference standard in support of investigator-initiated trial

Technical manufacturing assistance to get the sites started

Cross Reference to SOFIE's IND(s) or IND content to pursue investigator-initiated trial

Allows sites to expand their research program and grant opportunities

Process for access to FAPI precursor

Introductory Call



Application Completion



Application Approval



MTA Signature



Material Shipment




SOFIE and the FAPI team will be at SNMMI 2023 in Chicago

Visit us at the exhibit hall. Booth #6055

We have 3 posters that can be accessed on the
app or at science pavilion

- P230 Clinical development updates with [68Ga]FAPI-46 and [18F]FAPI-74
- P231 FAPI Global Outreach Program
- P261 Automated Production of [18F]FAPI-74 on the miniAllinOne Module

For FAPI-related inquiries, e-mail FAPIprogram@sofie.com





FAP Ligands for Imaging and Therapy

Sponsored by: SOFIE

FAP (fibroblast activation protein) as a diagnostic and therapeutic target for radiopharmaceuticals has seen many advances in recent years. This special session will bring together researchers and industry sponsors to discuss the latest progress in this space.

**Additional Industry
Participants**

Philogen
innovating targeting

POINT
BIOPHARMA

 **DC PHARMA**

DATE

Sunday, June 25th

TIME

6:30 pm - 8:30 pm

LOCATION

East/Lakeside Building
Room E451b

[Learn more about the symposium](#)

Light refreshments will be served.

Thank you

For FAPI-related inquiries, e-mail us: FAPIprogram@sofie.com